Utility/NN
of/IN
Integrated/JJ
Analysis/NN
of/IN
Pharmacogenomics/NNS
and/CC
Pharmacometabolomics/NNS
in/IN
Early/JJ
Phase/NN
Clinical/JJ
Trial/JJ
:/:
A/DT
Case/NN
Study/NN
of/IN
a/DT
New/JJ
Molecular/JJ
Entity/NN
./.
====================
In/IN
this/DT
report/NN
,/,
we/PRP
present/VBP
a/DT
case/NN
study/NN
of/IN
how/WRB
pharmacogenomics/NNS
and/CC
pharmacometabolomics/NNS
can/MD
be/VB
useful/JJ
to/TO
characterize/VB
safety/NN
and/CC
pharmacokinetic/JJ
profiles/NNS
in/IN
early/JJ
phase/NN
new/JJ
drug/NN
development/NN
clinical/JJ
trials/NNS
./.
====================
During/IN
conducting/VBG
a/DT
first-in-human/JJ
trial/JJ
for/IN
a/DT
new/JJ
molecular/JJ
entity/NN
,/,
we/PRP
were/VBD
able/JJ
to/TO
determine/VB
the/DT
mechanism/NN
of/IN
dichotomized/VBN
variability/NN
in/IN
plasma/NN
drug/NN
concentrations/NNS
,/,
which/WDT
appeared/VBD
closely/RB
related/JJ
to/TO
adverse/JJ
drug/NN
reactions/NNS
(/(
ADRs/NNS
)/)
through/IN
integrated/JJ
omics/NNS
analysis/NN
./.
====================
The/DT
pharmacogenomics/NNS
screening/NN
was/VBD
performed/VBN
from/IN
whole/JJ
blood/NN
samples/NNS
using/VBG
the/DT
Affymetrix/JJ
DMET/NN
(/(
Drug-Metabolizing/JJ
Enzymes/NNS
and/CC
Transporters/NNS
)/)
Plus/JJ
microarray/NN
,/,
and/CC
confirmation/NN
of/IN
genetic/JJ
variants/NNS
was/VBD
performed/VBN
using/VBG
real-time/JJ
polymerase/NN
chain/NN
reaction/NN
./.
====================
Metabolomics/NNS
profiling/VBG
was/VBD
performed/VBN
from/IN
plasma/NN
samples/NNS
using/VBG
liquid/JJ
chromatography/NN
coupled/VBN
with/IN
quadrupole/JJ
time-of-flight/JJ
mass/NN
spectrometry/NN
./.
====================
A/DT
GSTM1/NN
null/JJ
polymorphism/NN
was/VBD
identified/VBN
in/IN
pharmacogenomics/NNS
test/NN
and/CC
the/DT
drug/NN
concentrations/NNS
was/VBD
higher/JJR
in/IN
GSTM1/NN
null/JJ
subjects/NNS
than/IN
GSTM1/NN
functional/JJ
subjects/NNS
./.
====================
The/DT
apparent/JJ
drug/NN
clearance/NN
was/VBD
13-fold/RB
lower/JJR
in/IN
GSTM1/NN
null/JJ
subjects/NNS
than/IN
GSTM1/NN
functional/JJ
subjects/NNS
(/(
p/NN
</JJR
0.001/CD
)/)
./.
====================
By/IN
metabolomics/NNS
analysis/NN
,/,
we/PRP
identified/VBD
that/WDT
the/DT
study/NN
drug/NN
was/VBD
metabolized/VBN
by/IN
cysteinylglycine/NN
conjugation/NN
in/IN
GSTM/NN
functional/JJ
subjects/NNS
but/CC
those/DT
not/RB
in/IN
GSTM1/NN
null/JJ
subjects/NNS
./.
====================
The/DT
incidence/NN
rate/NN
and/CC
the/DT
severity/NN
of/IN
ADRs/NNS
were/VBD
higher/JJR
in/IN
the/DT
GSTM1/NN
null/JJ
subjects/NNS
than/IN
the/DT
GSTM1/NN
functional/JJ
subjects/NNS
./.
====================
Through/IN
the/DT
integrated/JJ
omics/NNS
analysis/NN
,/,
we/PRP
could/MD
understand/VB
the/DT
mechanism/NN
of/IN
inter-individual/JJ
variability/NN
in/IN
drug/NN
exposure/NN
and/CC
in/IN
adverse/JJ
response/NN
./.
====================
In/IN
conclusion/NN
,/,
integrated/VBN
multi-omics/NNS
analysis/NN
can/MD
be/VB
useful/JJ
for/IN
elucidating/VBG
the/DT
various/JJ
characteristics/NNS
of/IN
new/JJ
drug/NN
candidates/NNS
in/IN
early/JJ
phase/NN
clinical/JJ
trials/NNS
./.
====================
Improving/JJ
efficiency/NN
is/VBZ
an/DT
important/JJ
issue/NN
in/IN
new/JJ
drug/NN
development/NN
./.
====================
Although/IN
there/EX
have/VBP
been/VBN
considerable/JJ
advances/NNS
in/IN
science/NN
and/CC
technology/NN
,/,
the/DT
number/NN
of/IN
approved/JJ
new/JJ
drugs/NNS
per/IN
research/NN
spending/VBG
has/VBZ
continuously/RB
declined/VBD
over/IN
60/CD
years/NNS
[/(
1/CD
]/)
./.
====================
Dramatic/JJ
improvements/NNS
were/VBD
made/VBN
in/IN
pre-clinical/JJ
research/NN
areas/NNS
,/,
but/CC
the/DT
successful/JJ
clinical/JJ
development/NN
rate/NN
of/IN
new/JJ
drug/NN
candidates/NNS
has/VBZ
not/RB
changed/VBN
in/IN
recent/JJ
years/NNS
[/(
1/CD
]/)
./.
====================
To/TO
improve/VB
efficiency/NN
in/IN
clinical/JJ
trials/NNS
,/,
enrichment/JJ
strategies/NNS
were/VBD
proposed/VBN
in/IN
several/JJ
disease/NN
areas/NNS
,/,
which/WDT
enable/VBP
precision/NN
medicine/NN
in/IN
drug/NN
development/NN
[/(
2–4/CD
]/)
./.
====================
Various/JJ
omics/NNS
technologies/NNS
have/VBP
been/VBN
used/VBN
in/IN
recent/JJ
clinical/JJ
trials/NNS
to/TO
elucidate/VB
the/DT
various/JJ
characteristics/NNS
of/IN
new/JJ
drug/NN
candidates/NNS
and/CC
to/TO
identify/VB
optimal/JJ
subjects/NNS
for/IN
the/DT
trials/NNS
[/(
5–10/CD
]/)
./.
====================
Pharmacogenomics/NNS
is/VBZ
used/VBN
in/IN
clinical/JJ
trials/NNS
to/TO
select/VB
appropriate/JJ
patients/NNS
and/CC
to/TO
further/RBR
explain/VB
pharmacokinetics/NNS
,/,
pharmacodynamics/NNS
,/,
efficacy/NN
,/,
and/CC
adverse/JJ
drug/NN
reactions/NNS
of/IN
new/JJ
drug/NN
candidates/NNS
[/(
6–8/CD
]/)
./.
====================
Pharmacometabolomics/NNS
can/MD
be/VB
used/VBN
in/IN
clinical/JJ
trials/NNS
to/TO
identify/VB
drug/NN
targets/NNS
,/,
diagnosis/NN
disease/NN
,/,
assess/VB
drug/NN
metabolic/JJ
enzyme/NN
function/NN
in/IN
humans/NNS
,/,
and/CC
monitor/VB
the/DT
drug/NN
response/NN
and/CC
toxicity/NN
[/(
9–13/CD
]/)
./.
====================
The/DT
importance/NN
of/IN
those/DT
evaluations/NNS
is/VBZ
high/JJ
in/IN
early/JJ
phase/NN
clinical/JJ
trials/NNS
because/IN
it/PRP
can/MD
help/VB
to/TO
simplify/VB
late/JJ
phase/NN
clinical/JJ
trials/NNS
and/CC
increase/VBP
the/DT
probability/NN
of/IN
success/NN
of/IN
clinical/JJ
trials/NNS
[/(
5/CD
]/)
./.
====================
In/IN
this/DT
report/NN
,/,
we/PRP
present/VBP
a/DT
case/NN
showing/VBG
how/WRB
pharmacogenomics/NNS
and/CC
pharmacometabolomics/NNS
were/VBD
used/VBN
in/IN
an/DT
early/JJ
phase/NN
new/JJ
drug/NN
development/NN
clinical/JJ
trials/NNS
./.
====================
Drug/NN
X/NN
is/VBZ
a/DT
transient/JJ
receptor/NN
potential/JJ
vanilloid/NN
type/NN
1/CD
(/(
TRPV1/NN
)/)
antagonist/NN
class/NN
of/IN
new/JJ
drug/NN
candidate/NN
that/DT
is/VBZ
under/IN
clinical/JJ
development/NN
for/IN
the/DT
treatment/NN
of/IN
atopic/JJ
dermatitis/NN
./.
====================
In/IN
a/DT
first-in-human/JJ
clinical/JJ
trial/JJ
for/IN
drug/NN
X/NN
,/,
large/JJ
inter-individual/JJ
variability/NN
in/IN
the/DT
plasma/NN
concentration/NN
was/VBD
observed/VBN
after/IN
a/DT
single/JJ
oral/JJ
administration/NN
./.
====================
Furthermore/RB
,/,
moderate/JJ
adverse/JJ
drug/NN
reactions/NNS
were/VBD
observed/VBN
in/IN
certain/JJ
group/NN
of/IN
subjects/NNS
./.
====================
To/TO
perform/VB
subsequent/JJ
clinical/JJ
trials/NNS
safely/RB
and/CC
efficiently/RB
,/,
we/PRP
needed/VBD
to/TO
understand/VB
the/DT
cause/NN
of/IN
the/DT
inter-individual/JJ
variability/NN
observed/VBN
in/IN
the/DT
early/JJ
phase/NN
clinical/JJ
trial/JJ
for/IN
drug/NN
X/NN
./.
====================
The/DT
aim/NN
of/IN
this/DT
study/NN
was/VBD
to/TO
investigate/VB
the/DT
mechanism/NN
of/IN
the/DT
variability/NN
in/IN
plasma/NN
concentration/NN
of/IN
drug/NN
X/NN
and/CC
the/DT
adverse/JJ
drug/NN
reaction/NN
by/IN
integrated/JJ
multi-omics/NNS
analysis/NN
using/VBG
pharmacogenomics/NNS
and/CC
pharmacometabolomics/NNS
tools/NNS
./.
====================
Study/NN
samples/NNS
====================
The/DT
first-in-human/JJ
clinical/JJ
study/NN
enabled/VBD
exploratory/JJ
analysis/NN
of/IN
pharmacogenomics/NNS
and/CC
pharmacometabolomic/JJ
analysis/NN
./.
====================
The/DT
study/NN
was/VBD
approved/VBN
by/IN
the/DT
Institutional/JJ
Review/NN
Board/JJ
of/IN
Seoul/JJ
National/JJ
University/NN
Hospital/JJ
,/,
Seoul/JJ
,/,
Korea/NN
(/(
H-1011-027-339/NN
)/)
and/CC
was/VBD
conducted/VBN
in/IN
accordance/NN
with/IN
the/DT
principles/NNS
of/IN
the/DT
Declaration/NN
of/IN
Helsinki/JJ
and/CC
ICH/NN
Good/NN
Clinical/JJ
Practice/NN
./.
====================
All/DT
subjects/NNS
provided/VBD
written/CD
informed/VBN
consent/NN
before/IN
any/DT
study-related/JJ
procedure/NN
was/VBD
performed/VBN
./.
====================
Whole/IN
blood/NN
samples/NNS
(/(
n/NN
=/JJ
32/CD
)/)
were/VBD
obtained/VBN
from/IN
every/DT
subject/JJ
who/WP
received/VBD
a/DT
single/JJ
oral/JJ
dose/NN
of/IN
drug/NN
X/NN
for/IN
the/DT
pharmacogenomic/JJ
genotyping/VBG
./.
====================
Plasma/NN
samples/NNS
(/(
n/NN
=/JJ
8/CD
)/)
were/VBD
obtained/VBN
from/IN
the/DT
subjects/NNS
who/WP
received/VBD
highest/JJS
dose/NN
of/IN
drug/NN
X/NN
for/IN
the/DT
pharmacometabolomic/JJ
analysis/NN
./.
====================
Genotyping/VBG
====================
Genomic/JJ
DNA/NN
was/VBD
extracted/VBN
from/IN
the/DT
whole/JJ
blood/NN
using/VBG
a/DT
QIAamp/NN
DNA/NN
Mini/NN
Kit/NN
(/(
QIAgen/NN
,/,
Hilden/JJ
,/,
Germany/NNP
)/)
./.
====================
The/DT
pharmacogenomics/NNS
screening/NN
was/VBD
performed/VBN
using/VBG
an/DT
Affymetrix/JJ
DMET/NN
(/(
Drug-Metabolizing/JJ
Enzymes/NNS
and/CC
Transporters/NNS
)/)
Plus/JJ
microarray/NN
(/(
Affymetrix/JJ
,/,
Santa/NN
Clara/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
at/IN
DNA/NN
Link/NN
Co./NNP
Ltd./NNP
(/(
Seoul/JJ
,/,
Korea/NN
)/)
according/VBG
to/TO
the/DT
previously/RB
described/VBN
method/NN
[/(
14/CD
]/)
./.
====================
The/DT
microarray/NN
covered/VBD
1,931/CD
single/JJ
nucleotide/NN
polymorphisms/NNS
(/(
SNPs/NNS
)/)
and/CC
small/JJ
insertions/deletions/NNS
(/(
indels/VBZ
)/)
and/CC
5/CD
copy-number/NN
variations/NNS
for/IN
255/CD
genes/NNS
involved/VBN
in/IN
the/DT
metabolism/NN
,/,
transport/VBP
,/,
and/CC
excretion/NN
of/IN
drugs/NNS
in/IN
humans/NNS
and/CC
its/PRP$
utility/NN
and/CC
robustness/JJ
has/VBZ
been/VBN
validated/VBN
in/IN
previous/JJ
reports/NNS
[/(
15/CD
,/,
16/CD
]/)
./.
====================
Furthemore/RB
,/,
a/DT
real-time/JJ
polymerase/NN
chain/NN
reaction/NN
(/(
PCR/NN
)/)
was/VBD
performed/VBN
using/VBG
TaqMan/JJ
SNP/NN
Genotyping/JJ
Assays/NNS
(/(
Applied/VBN
Biosystems/NNS
,/,
Foster/NN
City/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
to/TO
confirm/VB
the/DT
GSTM1/NN
copy/NN
number/NN
variant/JJ
identified/VBN
from/IN
the/DT
microarray/NN
./.
====================
Pharmacometabolomic/JJ
analyses/NNS
====================
Metabolomic/JJ
profiling/VBG
to/TO
identify/VB
metabolites/NNS
of/IN
drug/NN
X/NN
was/VBD
performed/VBN
in/IN
plasma/NN
samples/NNS
using/VBG
liquid/JJ
chromatography/NN
(/(
Agilent/JJ
1200/CD
series/NNS
,/,
Agilent/JJ
Technologies/NNS
,/,
Santa/NN
Clara/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
coupled/VBN
with/IN
quadrupole/JJ
time-of-flight/JJ
mass/NN
spectrometry/NN
(/(
Agilent/JJ
6530/CD
Q-TOF/NN
MS/NN
,/,
Agilent/JJ
Technologies/NNS
)/)
./.
====================
To/TO
prepare/VB
the/DT
analyte/NN
,/,
a/DT
100/CD
μL/NN
of/IN
plasma/NN
sample/NN
was/VBD
mixed/VBN
with/IN
400/CD
μL/NN
of/IN
acetonitrile/JJ
./.
====================
Five/CD
microliters/NNS
of/IN
supernatant/JJ
aliquot/RB
was/VBD
injected/VBN
onto/IN
the/DT
Agilent/JJ
Zorbax/NN
C18/NN
column/NN
(/(
1.8/CD
μm/RB
particle/NN
size/NN
,/,
2.1/CD
×/CD
50/CD
mm/NN
;/:
Agilent/JJ
Technologies/NNS
)/)
at/IN
30°C/NN
under/IN
gradient/JJ
elution/NN
for/IN
18/CD
min/NN
./.
====================
The/DT
mobile/JJ
phase/NN
consisted/JJ
of/IN
a/DT
mixture/NN
of/IN
0.1/CD
%/NN
formic/JJ
acid/NN
in/IN
2/CD
mM/NN
ammonium/NN
formate/VBP
and/CC
0.1/CD
%/NN
formic/JJ
acid/NN
in/IN
acetonitrile/JJ
./.
====================
Positive/JJ
ion/NN
electrospray/NN
ionization/NN
mode/NN
was/VBD
used/VBN
for/IN
mass/NN
spectrometry/NN
./.
====================
The/DT
phase/NN
I/NN
and/CC
phase/NN
II/CD
metabolites/NNS
of/IN
drug/NN
X/NN
were/VBD
identified/VBN
by/IN
molecular/JJ
feature/NN
extraction/NN
of/IN
Agilent/JJ
MassHunter/NN
Qualitative/JJ
Software/JJ
version/NN
B.03.01/NN
(/(
Agilent/JJ
Technologies/NNS
)/)
./.
====================
Data/NNS
analysis/NN
====================
The/DT
pharmacokinetic/JJ
parameters/NNS
of/IN
drug/NN
X/NN
were/VBD
analyzed/VBN
by/IN
noncompartmental/JJ
analysis/NN
and/CC
presented/VBN
using/VBG
descriptive/JJ
statistics/NNS
./.
====================
The/DT
maximum/JJ
plasma/NN
concentration/NN
(/(
Cmax/NN
)/)
and/CC
the/DT
area/NN
under/IN
the/DT
plasma/NN
concentration-time/NN
curve/JJ
from/IN
0/CD
to/TO
the/DT
last/JJ
measurable/JJ
concentration/NN
(/(
AUClast/NN
)/)
,/,
which/WDT
represents/VBZ
the/DT
systemic/JJ
exposure/NN
to/TO
drug/NN
x/CC
,/,
is/VBZ
summarized/VBN
by/IN
genotype/NN
and/CC
dose/NN
groups/NNS
./.
====================
The/DT
apparent/JJ
clearance/NN
(/(
CL/F/NN
)/)
,/,
which/WDT
represents/VBZ
the/DT
capacity/NN
of/IN
drug/NN
elimination/NN
from/IN
the/DT
body/NN
,/,
was/VBD
pooled/JJ
among/IN
the/DT
dose/NN
groups/NNS
,/,
and/CC
the/DT
Mann–Whitney/JJ
U/NNP
test/VB
was/VBD
used/VBN
to/TO
compare/VB
the/DT
CL/F/NN
between/IN
the/DT
genotype/NN
groups/NNS
./.
====================
A/DT
p-value/JJ
of/IN
</JJR
0.05/CD
was/VBD
considered/VBN
to/TO
be/VB
statistically/RB
significant/JJ
./.
====================
The/DT
number/NN
of/IN
drug-related/JJ
adverse/JJ
events/NNS
(/(
AEs/NNS
)/)
between/IN
the/DT
genotype/NN
groups/NNS
was/VBD
compared/VBN
using/VBG
the/DT
chi-square/NN
test/NN
and/CC
Fisher/RB
’/CD
s/NNS
exact/JJ
test/NN
./.
====================
Statistical/JJ
analyses/NNS
were/VBD
performed/VBN
using/VBG
SAS/NN
software/JJ
version/NN
9.3/CD
(/(
SAS/NN
Institute/JJ
Inc./NNP
,/,
Cary/NN
,/,
NC/NN
,/,
USA/NN
)/)
./.
====================
Subject/NN
classification/NN
and/CC
study/NN
flow/NN
====================
After/IN
pharmacokinetics/NNS
and/CC
safety/NN
assessment/NN
of/IN
the/DT
original/JJ
first-in-human/JJ
clinical/JJ
study/NN
,/,
the/DT
subjects/NNS
were/VBD
clearly/RB
classified/VBN
into/IN
two/CD
groups/NNS
,/,
namely/RB
,/,
slow/JJ
and/CC
fast/JJ
metabolizers/NNS
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
After/IN
the/DT
classification/NN
,/,
genomic/JJ
marker/NN
exploration/NN
was/VBD
performed/VBN
by/IN
pharmacogenomic/JJ
analysis/NN
and/CC
metabolic/JJ
pathway/NN
identification/NN
was/VBD
performed/VBN
by/IN
drug/NN
pharmacometabolomic/JJ
analysis/NN
./.
====================
The/DT
genomic/JJ
marker/NN
data/NNS
was/VBD
integrated/VBN
with/IN
metabolic/JJ
pathway/NN
data/NNS
to/TO
understand/VB
the/DT
mechanism/NN
of/IN
the/DT
inter-individual/JJ
variability/NN
./.
====================
The/DT
overall/JJ
study/NN
flow/NN
is/VBZ
presented/VBN
in/IN
Fig/NN
./.
====================
2/CD
./.
====================
Pharmacogenomics/NNS
analysis/NN
results/VBZ
====================
In/IN
the/DT
slow/JJ
metabolizer/NN
subjects/NNS
,/,
homozygous/JJ
deletion/NN
of/IN
the/DT
glutathione-S-transferase/NN
M1/NN
gene/NN
(/(
GSTM1/NN
null/JJ
)/)
,/,
which/WDT
leads/VBZ
to/TO
loss/NN
of/IN
enzyme/NN
function/NN
,/,
was/VBD
identified/VBN
from/IN
the/DT
DMET/NN
Plus/JJ
microarray/NN
./.
====================
The/DT
systemic/JJ
exposure/NN
to/TO
drug/NN
X/NN
,/,
which/WDT
is/VBZ
represented/VBN
by/IN
the/DT
Cmax/NN
and/CC
the/DT
AUClast/JJ
,/,
was/VBD
higher/JJR
in/IN
GSTM1/NN
null/JJ
subjects/NNS
than/IN
GSTM1/NN
functional/JJ
subjects/NNS
in/IN
every/DT
dose/NN
group/NN
(/(
Table/JJ
1/CD
,/,
Fig/NN
./.
====================
2/CD
)/)
./.
====================
The/DT
apparent/JJ
drug/NN
clearance/NN
(/(
CL/F/NN
)/)
was/VBD
13-fold/RB
lower/JJR
in/IN
GSTM1/NN
null/JJ
subjects/NNS
than/IN
GSTM1/NN
functional/JJ
subjects/NNS
(/(
p/NN
</JJR
0.001/CD
)/)
(/(
Table/JJ
1/CD
)/)
./.
====================
The/DT
GSTM1/NN
deletion/NN
polymorphism/NN
was/VBD
confirmed/VBN
using/VBG
real-time/JJ
PCR/NN
,/,
and/CC
subjects/NNS
with/IN
two/CD
functional/JJ
GSTM1/NN
alleles/NNS
showed/VBD
similar/JJ
drug/NN
exposure/NN
to/TO
subjects/NNS
with/IN
one/CD
functional/JJ
GSTM1/NN
allele/NN
(/(
Fig/NN
./.
====================
3/CD
)/)
./.
====================
Pharmacometabolomic/JJ
analyses/NNS
result/NN
====================
A/DT
total/JJ
of/IN
four/CD
metabolites/NNS
of/IN
drug/NN
X/NN
(/(
cysteine/NN
conjugation/NN
,/,
cysteinylglycine/NN
conjugation/NN
,/,
methylation/NN
,/,
oxidative/JJ
defluorination/NN
)/)
were/VBD
observed/VBN
from/IN
the/DT
plasma/NN
samples/NNS
./.
====================
Among/IN
these/DT
metabolites/NNS
,/,
cysteine/NN
and/CC
cysteinylglycine/NN
conjugation/NN
metabolites/NNS
were/VBD
detected/VBN
in/IN
functional/JJ
GSTM1/NN
subjects/NNS
,/,
but/CC
they/PRP
were/VBD
absent/JJ
in/IN
GSTM1/NN
null/JJ
subjects/NNS
(/(
Fig/NN
./.
====================
4/CD
)/)
./.
====================
The/DT
areas/NNS
under/IN
the/DT
peak/NN
for/IN
methylation/NN
and/CC
oxidative/JJ
defluorination/NN
metabolites/NNS
were/VBD
higher/JJR
in/IN
the/DT
GSTM1/NN
null/JJ
subjects/NNS
than/IN
the/DT
functional/JJ
GSTM1/NN
subjects/NNS
(/(
Fig/NN
./.
====================
4/CD
)/)
./.
====================
GSTM1/NN
null/JJ
genotype/NN
and/CC
drug-related/JJ
AE/NN
====================
The/DT
number/NN
of/IN
drug-related/JJ
AEs/NNS
and/CC
the/DT
number/NN
of/IN
subjects/NNS
with/IN
drug-related/JJ
AEs/NNS
were/VBD
higher/JJR
in/IN
the/DT
GSTM1/NN
null/JJ
subjects/NNS
than/IN
the/DT
GSTM1/NN
functional/JJ
subjects/NNS
,/,
although/IN
it/PRP
failed/VBD
to/TO
reach/VB
statistical/JJ
significance/NN
(/(
Table/JJ
2/CD
)/)
./.
====================
Furthermore/RB
,/,
the/DT
AEs/NNS
were/VBD
more/RBR
severe/JJ
in/IN
the/DT
GSTM1/NN
null/JJ
subjects/NNS
than/IN
the/DT
GSTM1/NN
functional/JJ
subjects/NNS
./.
====================
Three/CD
subjects/NNS
in/IN
the/DT
GSTM1/NN
null/JJ
group/NN
experienced/VBD
AEs/NNS
with/IN
moderate/JJ
severity/NN
,/,
whereas/IN
none/NN
in/IN
the/DT
GSTM1/NN
functional/JJ
group/NN
experienced/VBD
those/DT
AEs/NNS
./.
====================
Those/DT
AEs/NNS
were/VBD
feeling/JJ
hot/JJ
,/,
feeling/VBG
cold/JJ
and/CC
a/DT
burning/JJ
sensation/NN
,/,
and/CC
these/DT
sensations/NNS
are/VBP
frequently/RB
reported/VBN
AEs/NNS
in/IN
TRPV1/NN
antagonist/NN
class/NN
drugs/NNS
[/(
17/CD
,/,
18/CD
]/)
./.
====================
Through/IN
the/DT
integrated/JJ
omics/NNS
analysis/NN
,/,
we/PRP
could/MD
understand/VB
the/DT
reason/NN
for/IN
the/DT
inter-individual/JJ
pharmacokinetic/JJ
variability/NN
observed/VBN
in/IN
the/DT
first-in-human/JJ
trial/JJ
for/IN
drug/NN
X/NN
./.
====================
The/DT
GSTs/NNS
are/VBP
a/DT
group/NN
of/IN
phase/NN
II/CD
enzymes/NNS
that/WDT
play/VBP
an/DT
important/JJ
role/NN
in/IN
the/DT
biotransformation/NN
of/IN
various/JJ
xenobiotic/JJ
and/CC
endogenous/JJ
compounds/NNS
by/IN
conjugation/NN
with/IN
glutathione/NN
[/(
19/CD
]/)
./.
====================
GSTM1/NN
is/VBZ
a/DT
μ/JJ
class/NN
isoform/NN
of/IN
GST/NN
,/,
and/CC
the/DT
GSTM1/NN
gene/NN
is/VBZ
highly/RB
polymorphic/JJ
in/IN
humans/NNS
./.
====================
Homozygous/JJ
deletion/NN
of/IN
the/DT
GSTM1/NN
gene/NN
is/VBZ
observed/VBN
in/IN
various/JJ
ethnic/JJ
groups/NNS
,/,
and/CC
its/PRP$
frequency/NN
ranged/VBD
from/IN
29.6/CD
%/NN
to/TO
56.2/CD
%/NN
[/(
20/CD
,/,
21/CD
]/)
./.
====================
The/DT
frequency/NN
of/IN
GSTM1/NN
null/JJ
subjects/NNS
was/VBD
50/CD
%/NN
in/IN
this/DT
study/NN
,/,
consistent/JJ
with/IN
the/DT
previously/RB
reported/VBD
GSTM1/NN
null/JJ
frequency/NN
in/IN
Koreans/NNS
[/(
20/CD
]/)
./.
====================
The/DT
loss/NN
of/IN
catalytic/JJ
function/NN
is/VBZ
suggested/VBN
to/TO
be/VB
reason/NN
for/IN
decreased/VBN
systemic/JJ
clearance/NN
of/IN
drug/NN
X/NN
in/IN
GSTM1/NN
null/JJ
subjects/NNS
./.
====================
This/DT
hypothesis/NN
was/VBD
supported/VBN
by/IN
the/DT
metabolite/NN
analysis/NN
showing/VBG
that/IN
no/DT
cysteine/NN
conjugation/NN
or/CC
cysteinylglycine/NN
conjugation/NN
metabolites/NNS
of/IN
drug/NN
X/NN
were/VBD
observed/VBN
in/IN
GSTM1/NN
null/JJ
subjects/NNS
./.
====================
The/DT
effect/NN
of/IN
the/DT
GSTM1/NN
null/JJ
polymorphism/NN
on/IN
systemic/JJ
exposure/NN
to/TO
drug/NN
X/NN
was/VBD
reproduced/VBN
in/IN
subsequent/JJ
clinical/JJ
trials/NNS
./.
====================
The/DT
GSTM1/NN
null/JJ
subjects/NNS
showed/VBD
higher/JJR
plasma/NN
concentration/NN
and/CC
lower/JJR
CL/F/NN
of/IN
drug/NN
X/NN
than/IN
functional/JJ
GSTM1/NN
subjects/NNS
after/IN
multiple/JJ
oral/JJ
administrations/NNS
(/(
Table/JJ
3/CD
,/,
Fig/NN
./.
====================
5/CD
)/)
./.
====================
The/DT
clinical/JJ
development/NN
strategy/NN
for/IN
drug/NN
X/NN
needed/VBN
to/TO
be/VB
modified/VBN
to/TO
reflect/VB
these/DT
results/NNS
because/IN
the/DT
GSTM1/NN
null/JJ
variant/JJ
was/VBD
a/DT
major/JJ
determining/VBG
factor/NN
for/IN
drug/NN
exposure/NN
,/,
as/IN
well/RB
as/IN
drug-related/VBN
AEs/NNS
,/,
and/CC
because/IN
the/DT
frequency/NN
of/IN
GSTM1/NN
nulls/NNS
is/VBZ
approximately/RB
half/RB
of/IN
total/JJ
population/NN
./.
====================
A/DT
personalized/VBN
drug/NN
development/NN
strategy/NN
applying/VBG
different/JJ
oral/JJ
doses/NNS
based/VBN
on/IN
the/DT
GSTM1/NN
genotype/NN
or/CC
switching/NN
to/TO
a/DT
different/JJ
formulation/NN
with/IN
limited/JJ
systemic/JJ
exposure/NN
was/VBD
needed/VBN
for/IN
safe/JJ
and/CC
efficient/JJ
development/NN
of/IN
drug/NN
X./NNP
drug/NN
X/NN
is/VBZ
currently/RB
in/IN
clinical/JJ
development/NN
as/IN
a/DT
topical/JJ
formulation/NN
to/TO
limit/VB
systemic/JJ
absorption/NN
./.
====================
Integrated/JJ
multi-omics/NNS
analysis/NN
can/MD
be/VB
a/DT
useful/JJ
tool/NN
to/TO
evaluate/VB
the/DT
diverse/JJ
characteristics/NNS
of/IN
new/JJ
drug/NN
candidates/NNS
in/IN
clinical/JJ
situations/NNS
./.
====================
The/DT
importance/NN
of/IN
integration/NN
of/IN
multi-omics/NNS
data/NNS
is/VBZ
growing/VBG
in/IN
many/JJ
research/NN
areas/NNS
,/,
including/VBG
pharmaceutical/JJ
research/NN
and/CC
development/NN
[/(
22–24/CD
]/)
./.
====================
As/IN
shown/VBN
in/IN
this/DT
case/NN
study/NN
,/,
integrated/VBN
multi-omics/NNS
analysis/NN
can/MD
be/VB
used/VBN
to/TO
explain/VB
the/DT
cause/JJ
of/IN
inter-individual/JJ
variability/NN
in/IN
drug/NN
exposure/NN
and/CC
adverse/JJ
drug/NN
reactions/NNS
observed/VBN
in/IN
clinical/JJ
development/NN
./.
====================
This/DT
information/NN
can/MD
be/VB
important/JJ
when/WRB
making/VBG
decisions/NNS
for/IN
further/JJ
drug/NN
development/NN
strategy/NN
./.
====================
In/IN
conclusion/NN
,/,
integrated/VBN
multi-omics/NNS
analysis/NN
can/MD
be/VB
useful/JJ
in/IN
early/JJ
phase/NN
clinical/JJ
trials/NNS
for/IN
elucidating/VBG
the/DT
various/JJ
characteristics/NNS
of/IN
new/JJ
drug/NN
candidates/NNS
that/DT
could/MD
not/RB
be/VB
produced/VBN
through/IN
traditional/JJ
clinical/JJ
trial/JJ
methods/NNS
./.
====================
Plasma/NN
concentration-time/VBP
profiles/NNS
of/IN
drug/NN
X/NN
after/IN
single/JJ
oral/JJ
administration/NN
./.
====================
Study/NN
flow/NN
./.
====================
(/(
A–D/NN
)/)
Comparison/NN
of/IN
the/DT
pharmacokinetic/JJ
parameters/NNS
of/IN
drug/NN
X/NN
among/IN
the/DT
different/JJ
GSTM1/NN
genotype/NN
groups/NNS
./.
====================
GSTM1/NN
(/(
−/−/LS
)/)
,/,
subject/JJ
with/IN
glutathione-S-transferase/NN
M1/NN
null/JJ
function/NN
;/:
GSTM1/NN
(/(
−/+/JJ
)/)
,/,
subject/JJ
with/IN
one/CD
glutathione-S-transferase/NN
M1/NN
functional/JJ
allele/NN
;/:
GSTM1/NN
(/(
+/+/CC
)/)
,/,
subject/JJ
with/IN
two/CD
glutathione-S-trans-ferase/NN
M1/NN
functional/JJ
allele/NN
;/:
Cmax/NN
,/,
maximum/JJ
plasma/NN
concentration/NN
;/:
AUClast/RB
,/,
area/NN
under/IN
the/DT
plasma/NN
concentration-time/NN
curve/JJ
from/IN
0/CD
to/TO
the/DT
last/JJ
measurable/JJ
concentration/NN
./.
====================
(/(
A–D/NN
)/)
Plasma/NN
drug/NN
X/NN
meta-bolite-time/NN
profiles/NNS
after/IN
single/JJ
oral/JJ
administration/NN
./.
====================
Plasma/NN
concentration-time/VBP
profiles/NNS
of/IN
drug/NN
X/NN
after/IN
multiple/JJ
oral/JJ
administration/NN
./.
====================
GSTM1/NN
(/(
−/−/CD
)/)
,/,
subject/JJ
with/IN
glutathione-S-transferase/NN
M1/NN
null/JJ
function/NN
;/:
GSTM1/NN
(/(
−/+/JJ
)/)
,/,
subject/JJ
with/IN
one/CD
glutathione-S-transferase/NN
M1/NN
functional/JJ
allele/NN
./.
====================
Pharmacokinetic/JJ
parameters/NNS
of/IN
drug/NN
X/NN
following/VBG
single/JJ
oral/JJ
dose/NN
====================
Summary/JJ
of/IN
drug-related/JJ
AEs/NNS
====================
Pharmacokinetic/JJ
parameters/NNS
of/IN
drug/NN
X/NN
following/VBG
multiple/JJ
oral/JJ
doses/NNS
====================
